The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Table 1 Characteristics and adverse events from ICI monotherapy studies

Study	Patients	Therapy (dose)	Hypothyroid events of any grade (%)	Hypothyroid events of grade 3–5	Median follow-up (range)
Westin [1]	29	Pidilizumab (3 mg/kg)	0 (0)	0	15.4 months
Weber [2]	452	Nivolumab (3 mg/kg)	49 (10.8)	1	19.5 months/13 months^a
Bellmunt [3]	266	Pembrolizumab	17 (6.4)^b	0	14.1 months
Herbst [4]	339	Pembrolizumab (2 mg/kg)	28 (8.3)	0	13.1 months (8.6–17–7)

^aAdverse events were reported up to 30 days after last treatment and treatment duration was up to 12 months at a maximum, for that reason follow-up time regarding adverse events can add up to no more than 13 months
^b10 patients (3.8%) experienced hyperthyroidism

ISSN: 2162-3619